Health
CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A – News-Medical.Net
Researchers at Children’s Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia…
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies,…
-
Noosa News22 hours agoYoung voices shape Sunshine Coast’s future
-
Business22 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News21 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News20 hours agoAnother All-Star Cast, Another Tale of Family Chaos: The Trailer for Wes Anderson’s ‘The Phoenician Scheme’ Is Here